{
    "eid": "2-s2.0-85122570499",
    "title": "Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes",
    "cover-date": "2021-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Epidemiology",
            "@code": "2713",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Public Health, Environmental and Occupational Health",
            "@code": "2739",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "Erythropoiesis stimulating agents",
        "Erythropoietin level",
        "Gene mutations",
        "Low",
        "Risk myelodysplastic syndromes"
    ],
    "authors": [
        "Saroj Hattakitpanitchakul",
        "Sirorat Kobbuaklee",
        "Kitsada Wudhikarn",
        "Chantana Polprasert"
    ],
    "citedby-count": 0,
    "ref-count": 15,
    "ref-list": [
        "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia",
        "ITACA: A new validated international erythropoietic stimulating agentresponse score that further refines the predictive power of previous scoring systems",
        "Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia",
        "Validation and clinical impact of the oncomine myeloid targeted DNA and RNA ion semiconductor sequencing assay",
        "Myelodysplastic Syndromes, Version 3.2021",
        "Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br JHaematol, 99, 344-51. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al",
        "Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma",
        "Thrombotic complications of erythropoiesis-stimulating agents",
        "Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study",
        "Revisiting use of growth factors in myelodysplastic syndromes",
        "Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes",
        "The myelodysplastic syndromes: diagnosis and treatment",
        "Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Ratchadapiseksompotch Fund",
        "Research Unit in Translational Hematology",
        "Chulalongkorn University",
        "Thailand Research Fund",
        "Faculty of Medicine, Chulalongkorn University"
    ]
}